Anaspaz Side Effects
Generic name: hyoscyamine
Note: This document contains side effect information about hyoscyamine. Some of the dosage forms listed on this page may not apply to the brand name Anaspaz.
Some side effects of Anaspaz may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to hyoscyamine: oral conventional tablets and sublingual tablets, oral extended-release capsules and tablets, oral oral solution and elixir, oral orally disintegrating tablets, parenteral injection
Side effects include:
Most adverse effects are manifestations of pharmacologic effects at muscarinic-cholinergic receptors and usually are reversible when therapy is discontinued.
Severity and frequency of adverse effects are dose related and individual intolerance varies greatly; adverse effects occasionally may be obviated by a reduction in dosage but this also may eliminate potential therapeutic effects.
Adverse effects include dry mouth, urinary hesitancy and retention, blurred vision, tachycardia, palpitations, mydriasis, increased ocular tension, loss of taste, headache, nervousness, drowsiness, weakness, fatigue, dizziness, insomnia, nausea, vomiting, impotence, constipation, bloated feeling, abdominal pain, diarrhea, allergic reactions or drug idiosyncrasies, urticaria and other dermal manifestations, ataxia, speech disturbance, mental confusion and/or excitement (especially in geriatric patients), short-term memory loss, hallucinations, and decreased sweating.
For Healthcare Professionals
Applies to hyoscyamine: compounding powder, injectable solution, oral capsule extended release, oral liquid, oral solution, oral spray, oral tablet, oral tablet chewable, oral tablet disintegrating, oral tablet extended release, sublingual tablet
Cardiovascular side effects have included tachycardia, premature ventricular depolarizations, and ventricular tachycardia.
Gastrointestinal side effects due to the anticholinergic effects of hyoscyamine (the active ingredient contained in Anaspaz) have commonly included dry mouth and mucous membranes. Other reported side effects include delayed gastric emptying time, reduced gastric acid secretion, constipation, and gastroesophageal reflux.
Hyoscyamine (the active ingredient contained in Anaspaz) toxicity (anticholinergic side effects) often presents as fever, tachycardia, agitation, and dry skin/mucous membranes.
Genitourinary complications include urinary retention (due to anticholinergic effects on the urinary sphincter), which is common and dose-related, and impotence in male patients.
Hypersensitivity reactions to hyoscyamine (the active ingredient contained in Anaspaz) are rare. Reactions can include urticaria, eczema, papillary hyperplasia, mucopurulent discharge, eosinophilia, pruritus, edema, hypotension, abdominal pain, tachypnea, nausea and vomiting.
Nervous system side effects have included lethargy and somnolence. Higher doses may be associated with mental confusion and/or excitement. The elderly appear to be more prone to the anticholinergic effects of hyoscyamine (the active ingredient contained in Anaspaz) on the CNS.
Ocular side effects due to the anticholinergic activity of hyoscyamine (the active ingredient contained in Anaspaz) have included inhibition of the iris sphincter muscle (possibly resulting in mydriasis), follicular conjunctivitis, and inhibition of the ciliary muscle (which can produce blurred vision). All muscarinic antagonists can precipitate glaucoma.
Endocrine side effects have included inhibition of exocrine sweat glands. This is usually not clinically significant except when perspiration becomes a major factor in body temperature control.
More Anaspaz resources
- Anaspaz Prescribing Information (FDA)
- Anaspaz MedFacts Consumer Leaflet (Wolters Kluwer)
- Anaspaz Concise Consumer Information (Cerner Multum)
- Hyoscyamine Monograph (AHFS DI)
- hyoscyamine MedFacts Consumer Leaflet (Wolters Kluwer)
- HyoMax Prescribing Information (FDA)
- Hyosyne drops MedFacts Consumer Leaflet (Wolters Kluwer)
- Hyosyne Prescribing Information (FDA)
- IB-Stat spray MedFacts Consumer Leaflet (Wolters Kluwer)
- Levbid extended-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Levsin Prescribing Information (FDA)
- Levsin SL Prescribing Information (FDA)
- NuLev orally disintegrating tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Symax Duotab Prescribing Information (FDA)
- Symax Duotab controlled-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Symax FasTab Prescribing Information (FDA)
- Symax SL Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.